Patients were randomly assigned ( 1:1 ) by computer-generated random sequence with an interactive voice-response system ( block size four , stratified by country and concomitant therapy ) to once-weekly exenatide ( 2 mg subcutaneous injection ) or once-daily glargine ( titrated to target ) to be given in addition to their existing oral glucose-lowering regimens .